KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Q3 2025 value amounting to $251.5 million.

  • Jazz Pharmaceuticals' Net Income towards Common Stockholders rose 1677.3% to $251.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$275.8 million, marking a year-over-year decrease of 15926.84%. This contributed to the annual value of $561.8 million for FY2024, which is 3444.83% up from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Net Income towards Common Stockholders of $251.5 million as of Q3 2025, which was up 1677.3% from -$718.4 million recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Net Income towards Common Stockholders registered a high of $251.5 million during Q3 2025, and its lowest value of -$718.4 million during Q2 2025.
  • Its 5-year average for Net Income towards Common Stockholders is -$1.7 million, with a median of $53.8 million in 2022.
  • In the last 5 years, Jazz Pharmaceuticals' Net Income towards Common Stockholders tumbled by 64182.59% in 2022 and then soared by 111653.14% in 2023.
  • Quarter analysis of 5 years shows Jazz Pharmaceuticals' Net Income towards Common Stockholders stood at -$32.3 million in 2021, then crashed by 641.83% to -$240.0 million in 2022, then skyrocketed by 139.43% to $94.6 million in 2023, then soared by 102.01% to $191.1 million in 2024, then skyrocketed by 31.56% to $251.5 million in 2025.
  • Its last three reported values are $251.5 million in Q3 2025, -$718.4 million for Q2 2025, and $191.1 million during Q4 2024.